EGFR and non-small cell lung carcinoma: EGFR‐TKI has been recommended as the first choice for advanced NSCLC patients with EGFR mutation on account of the fact that it can bring about longer progression‐free survival, less severe adverse events and prolongs survival in NSCLC patients who fail the chemotherapy regimens (Mitsudomi et al., 2010; Rosell et al., 2012; Shepherd et al., 2005).